Pancreatic Cancer Clinical Trials

• Age 18 or above.

• The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.

• There should be at least one measurable lesion.

• All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion/exclusion criteria.

• Have sufficient organ and bone marrow function

• Expected survival period ≥ 12 weeks

• Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.

• With my consent and signed informed consent form.

• Patients with a pathological diagnosis of pancreatic cancer (ductal adenocarcinoma or adenocarcinoma) have evidence of advanced or metastatic disease that is not resectable.

• Previously received no systemic treatment for unresectable locally advanced or metastatic pancreatic cancer.